Polyrizon Ltd. (PLRZ)
NASDAQ: PLRZ · Real-Time Price · USD
11.06
-0.39 (-3.41%)
At close: Jun 10, 2026, 4:00 PM EDT
11.90
+0.84 (7.59%)
After-hours: Jun 10, 2026, 7:04 PM EDT
Polyrizon Employees
As of December 31, 2025, Polyrizon had 4 total employees, including 2 full-time and 4 part-time employees. The number of employees decreased by 2 or -33.33% compared to the previous year.
Employees
4
Change (1Y)
-2
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$833,750
Market Cap
20.70M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 4 | -2 | -33.33% | 2 | 2 |
| Dec 31, 2024 | 6 | - | - | 2 | 4 |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 115 |
| Vistagen Therapeutics | 59 |
| CervoMed | 15 |
| Cellectar Biosciences | 11 |
| VYNE Therapeutics | 10 |
| AEON Biopharma | 8 |
| Allarity Therapeutics | 8 |
| Traws Pharma | 7 |
PLRZ News
- 16 hours ago - Polyrizon receives notice of European patent publication - TheFly
- 16 hours ago - Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology - GlobeNewsWire
- 2 days ago - Polyrizon signs agreements with two additional clinical sites for Nasarix study - TheFly
- 2 days ago - Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial - GlobeNewsWire
- 4 weeks ago - Polyrizon signs clinical trial agreement with clinical research site for Nasarix - TheFly
- 4 weeks ago - Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial - GlobeNewsWire
- 4 weeks ago - Pulse Equity: Emerging Outbreaks - Polyrizon's Approach to Broad and Rapidly Deployable Protection - PRNewsWire
- 5 weeks ago - Polyrizon amends patent application claims for intranasal drug delivery platform - TheFly